Literature DB >> 17108144

Receptor for activated C kinase 1 (RACK1) and Src regulate the tyrosine phosphorylation and function of the androgen receptor.

Sarah Kraus1, Daniel Gioeli, Tomas Vomastek, Vicki Gordon, Michael J Weber.   

Abstract

The androgen receptor (AR) remains functionally important in the development and progression of prostate cancer even when the disease seems androgen "independent." Because signal transduction by growth factor receptors increases in advanced prostate cancer and is capable of sensitizing the AR to androgen, there is considerable interest in determining the mechanisms by which signaling systems can modulate AR function. We show herein that the adaptor/scaffolding protein receptor for activated C kinase 1 (RACK1), which was previously reported to interact with the AR, modulates the tyrosine phosphorylation of AR and its interaction with the Src tyrosine kinase. We also show that down-regulation of RACK1 by short interfering RNA inhibits growth and stimulates prostate-specific antigen transcription in androgen-treated prostate cancer cells. Our results suggest that RACK1 mediates the cross-talk of AR with additional binding partners, such as Src, and facilitates the tyrosine phosphorylation and transcriptional activity of the AR.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17108144     DOI: 10.1158/0008-5472.CAN-06-0596

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  58 in total

1.  The RNA-binding protein SERBP1 interacts selectively with the signaling protein RACK1.

Authors:  Graeme B Bolger
Journal:  Cell Signal       Date:  2017-03-04       Impact factor: 4.315

2.  Stxbp4 regulates DeltaNp63 stability by suppression of RACK1-dependent degradation.

Authors:  Yingchun Li; Melissa J Peart; Carol Prives
Journal:  Mol Cell Biol       Date:  2009-05-18       Impact factor: 4.272

Review 3.  Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion.

Authors:  William P Harris; Elahe A Mostaghel; Peter S Nelson; Bruce Montgomery
Journal:  Nat Clin Pract Urol       Date:  2009-02

4.  v-Src Oncogene Induces Trop2 Proteolytic Activation via Cyclin D1.

Authors:  Xiaoming Ju; Xuanmao Jiao; Adam Ertel; Mathew C Casimiro; Gabriele Di Sante; Shengqiong Deng; Zhiping Li; Agnese Di Rocco; Tingting Zhan; Adam Hawkins; Tanya Stoyanova; Sebastiano Andò; Alessandro Fatatis; Michael P Lisanti; Leonard G Gomella; Lucia R Languino; Richard G Pestell
Journal:  Cancer Res       Date:  2016-09-15       Impact factor: 12.701

5.  CCR5 receptor antagonists block metastasis to bone of v-Src oncogene-transformed metastatic prostate cancer cell lines.

Authors:  Daniela Sicoli; Xuanmao Jiao; Xiaoming Ju; Marco Velasco-Velazquez; Adam Ertel; Sankar Addya; Zhiping Li; Sebastiano Andò; Alessandro Fatatis; Bishnuhari Paudyal; Massimo Cristofanilli; Mathew L Thakur; Michael P Lisanti; Richard G Pestell
Journal:  Cancer Res       Date:  2014-12-01       Impact factor: 12.701

6.  Effect of Ack1 tyrosine kinase inhibitor on ligand-independent androgen receptor activity.

Authors:  Kiran Mahajan; Sridevi Challa; Domenico Coppola; Harshani Lawrence; Yunting Luo; Harsukh Gevariya; Weiwei Zhu; Y Ann Chen; Nicholas J Lawrence; Nupam P Mahajan
Journal:  Prostate       Date:  2010-09-01       Impact factor: 4.104

Review 7.  Pathogenic mechanisms and therapeutic strategies in spinobulbar muscular atrophy.

Authors:  Jason P Chua; Andrew P Lieberman
Journal:  CNS Neurol Disord Drug Targets       Date:  2013-12       Impact factor: 4.388

8.  2,2-bis(4-chlorophenyl)-1,1-dichloroethylene stimulates androgen independence in prostate cancer cells through combinatorial activation of mutant androgen receptor and mitogen-activated protein kinase pathways.

Authors:  Supriya Shah; Janet K Hess-Wilson; Siobhan Webb; Hannah Daly; Sonia Godoy-Tundidor; Jae Kim; Joanne Boldison; Yehia Daaka; Karen E Knudsen
Journal:  Mol Cancer Res       Date:  2008-09       Impact factor: 5.852

Review 9.  Targeting the androgen receptor pathway in prostate cancer.

Authors:  Yu Chen; Charles L Sawyers; Howard I Scher
Journal:  Curr Opin Pharmacol       Date:  2008-08-12       Impact factor: 5.547

10.  Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases.

Authors:  Y Liu; M Karaca; Z Zhang; D Gioeli; H S Earp; Y E Whang
Journal:  Oncogene       Date:  2010-04-12       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.